Yumab

Yumab GmbH is a leading German biotechnology company specializing in the rapid discovery and engineering of fully human therapeutic antibodies using proprietary phage display platforms. The company offers contract research services from target identification through lead optimization, leveraging advanced technologies such as large universal antibody libraries, high-throughput screening, mammalian cell display systems, and AI-driven design. Yumab collaborates globally with pharma/biotech partners to deliver de-risked leads for next-generation biologics across multiple disease areas. It does not market its own therapeutics but enables clients’ pipelines through service offerings.